# RELATIVITY-020 (NCT01968109)

> An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

No report yet. It can be ordered.

- Drugs tested: relatlimab plus nivolumab; relatlimab; BMS-986213
- Indication: advanced solid tumors

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01968109
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Bristol-Myers Squibb
- Conditions: Neoplasms by Site
- Interventions: Relatlimab; Nivolumab; BMS-986213
- Enrollment: 1482
- Primary outcome: Number of Participants With Adverse Events, Deaths and Clinically Relevant Laboratory Abnormalities
- Primary outcome: Part C, D1, D2, E - Objective Response Rate Per BICR
- Primary outcome: Part C, D1, D2, E - Disease Control Rate (DCR) Per BICR
- Primary outcome: Part C, D1, D2, E - Duration of Response (DOR) Per BICR
- Primary outcome: Part D1: Number of Participants With Adverse Events in the Broad Scope Standardized MedDRA (SMQ) Anaphylactic Reaction Occurring Within 2 Days of Any Doses of Study Therapy
- Primary outcome: Part C, D1, D2, E - Objective Response Rate Per BICR

## Indexed commentary on RELATIVITY-020 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 6 YouTube videos
- 6 podcast episodes
- 3 posts on X

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=relativity-020-nct01968109

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01968109", "email": "<work email>"}; the inbox owner confirms by the emailed link.